Last edition
News about "Drug Linerixibat"
GSK Licenses Liver Disease Drug Linerixibat To Alfasigma In USD 690 Million Deal
GSK plc has entered into a global licensing agreement with Alfasigma S.p.A., granting the Italian drugmaker exclusive worldwide rights to develop, manufacture and commercialise linerixibat, an investigational therapy for cholestatic pruritus associated with primary biliary cholangitis (PBC).
Drug Linerixibat | 10/03/2026 | By Darshana | 107
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members